Johnson & Johnson to Invest Over $1 Billion in Pennsylvania Cell Therapy Facility
Johnson & Johnson will invest more than $1 billion to build a cell therapy manufacturing facility in Pennsylvania to support commercial-scale production of autologous and allogeneic treatments. JNJ’s subcutaneous Darzalex franchise drove higher royalty payments to Halozyme, contributing to a 51% year-over-year increase in Halozyme’s Q4 royalty revenue.
1. Cell Therapy Facility Investment
Johnson & Johnson will spend over $1 billion to construct a new cell therapy manufacturing plant in Pennsylvania, designed to handle commercial-scale autologous and allogeneic treatments for its pipeline. The facility is expected to enhance production capacity and support late-stage cell therapy candidates under development.
2. Subcutaneous Darzalex Royalty Growth
J&J’s subcutaneous formulation of Darzalex drove a 51% year-over-year jump in Halozyme’s Q4 royalty revenues to $258 million, indicating increasing adoption of the therapy. This robust royalty stream underscores the market’s uptake of J&J’s Darzalex franchise and its contribution to partner earnings.